Corcept Therapeutics announced that the Court for the District of New Jersey ruled in favor of Teva Pharmaceuticals, stating that Teva does not infringe on Corcept's patents related to administering Korlym with CYP3A4 inhibitors.
AI Assistant
CORCEPT THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.